SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain.

COVID-19 Delta variant Omicron variant SARS SARS-CoV-2 Spain contact tracing coronavirus coronavirus disease respiratory infections secondary attack rate severe acute respiratory syndrome coronavirus 2 vaccine effectiveness viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
10 2022
Historique:
pubmed: 30 8 2022
medline: 24 9 2022
entrez: 29 8 2022
Statut: ppublish

Résumé

We performed a prospective, cross-sectional study of household contacts of symptomatic index case-patients with SARS-CoV-2 infection during the shift from Delta- to Omicron-dominant variants in Spain. We included 466 household contacts from 227 index cases. The secondary attack rate was 58.2% (95% CI 49.1%-62.6%) during the Delta-dominant period and 80.9% (95% CI 75.0%-86.9%) during the Omicron-dominant period. During the Delta-dominant period, unvaccinated contacts had higher probability of infection than vaccinated contacts (odds ratio 5.42, 95% CI 1.6-18.6), but this effect disappeared at ≈20 weeks after vaccination. Contacts showed a higher relative risk of infection (9.16, 95% CI 3.4-25.0) in the Omicron-dominant than Delta-dominant period when vaccinated within the previous 20 weeks. Our data suggest vaccine evasion might be a cause of rapid spread of the Omicron variant. We recommend a focus on developing vaccines with long-lasting protection against severe disease, rather than only against infectivity.

Identifiants

pubmed: 36037811
doi: 10.3201/eid2810.220494
pmc: PMC9514368
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1999-2008

Références

N Engl J Med. 2021 Aug 19;385(8):759-760
pubmed: 34161702
Nat Med. 2022 May;28(5):1063-1071
pubmed: 35189624
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166
pubmed: 34437519
Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
Lancet Infect Dis. 2022 Feb;22(2):183-195
pubmed: 34756186
Emerg Infect Dis. 2022 Mar;28(3):591-598
pubmed: 35195514
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Euro Surveill. 2021 Sep;26(39):
pubmed: 34596016
J Health Econ. 2021 Dec;80:102530
pubmed: 34563830
Emerg Infect Dis. 2021 Dec;27(12):3009-3019
pubmed: 34695369
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
PLoS One. 2021 Jun 16;16(6):e0249499
pubmed: 34133415
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
JAMA Intern Med. 2021 Oct 1;181(10):1343-1350
pubmed: 34424260
MMWR Morb Mortal Wkly Rep. 2022 Mar 04;71(9):341-346
pubmed: 35238860
Front Physiol. 2021 Jan 12;11:571416
pubmed: 33510644
J Infect Dis. 2022 Apr 1;225(7):1129-1140
pubmed: 34888688
Int J Environ Res Public Health. 2022 Jun 30;19(13):
pubmed: 35805724
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
JAMA Netw Open. 2022 Apr 1;5(4):e229317
pubmed: 35482308
Euro Surveill. 2020 May;25(21):
pubmed: 32489179
J Infect Dis. 2021 Jan 4;223(1):62-71
pubmed: 33175145
JAMA Netw Open. 2021 Aug 2;4(8):e2122240
pubmed: 34448865
Emerg Infect Dis. 2022 May;28(5):998-1001
pubmed: 35290176
Lancet Infect Dis. 2022 Sep;22(9):1313-1320
pubmed: 35658998
Lancet. 2022 Jan 8;399(10320):152-160
pubmed: 34741818
Lancet Infect Dis. 2022 Feb;22(2):e52-e58
pubmed: 34534512
J Infect. 2020 Sep;81(3):357-371
pubmed: 32615199
JAMA Netw Open. 2021 Mar 1;4(3):e211085
pubmed: 33688964
Open Forum Infect Dis. 2022 Feb 20;9(5):ofac066
pubmed: 35392460
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Emerg Microbes Infect. 2022 Dec;11(1):337-343
pubmed: 34935594
N Engl J Med. 2022 Jan 27;386(4):340-350
pubmed: 35021002
Euro Surveill. 2021 Apr;26(15):
pubmed: 33860747
Public Health. 2021 Jun;195:132-134
pubmed: 34111802
Prev Med. 2022 Jan;154:106890
pubmed: 34800471
J Korean Med Sci. 2022 Jan 03;37(1):e12
pubmed: 34981682

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH